Cadre Holds $736M-$758M Sales View; Record Backlog, 19% Q1 Growth

Cadre Holdings (CDRE) started fiscal 2026 by reaffirming its full-year net sales outlook of $736 million to $758 million. The company also reported a record $355 million backlog and a 19% jump in first-quarter sales. The surface read is that a record backlog de-risks the full-year number. The market read is more specific: the composition of that backlog, the absence of a guidance raise despite the strong quarter, and the pending margin delivery from the TYR Tactical and Alien Gear Holsters acquisitions are now the only variables that matter.

$736M-$758M Guidance Reaffirmed: Record Backlog, No Raise

Cadre kept its 2026 net sales outlook unchanged, bracketing the year between $736 million and $758 million. That decision, coming alongside a record $355 million backlog, tells you the acquisitions of TYR Tactical and Alien Gear Holsters contributed heavily to the order book. They did not immediately unlock a higher revenue forecast. The simple thesis is that a record backlog de-risks the full-year number. The better read is that backlog composition and conversion timing now dominate.

Acquired backlogs often carry different margin profiles and revenue recognition schedules than the legacy business. A surge from closed deals can front-load backlog without signaling the same organic demand that would justify a guidance bump. If a meaningful portion of the $355 million sits in longer-dated defense contracts with lower-margin pass-through components, the headline number overstates near-term earnings power. Conversely, if the backlog is concentrated in shorter-cycle commercial safety products that turn into revenue within two quarters, Cadre could end the year above the high end of guidance without ever raising it.

Q1 Sales Up 19%: Deals Booked, Organic Growth Unclear

First-quarter sales rose 19% year over year, the first print that includes contributions from TYR Tactical and Alien Gear Holsters. Cadre did not break out organic growth, leaving investors to parse whether the jump was entirely deal-driven or whether the base business is accelerating. With the full-year guide unchanged, the implied organic growth rate becomes the real debate.

A 19% headline gain that does not pull full-year guidance higher typically signals one of two things: management is embedding conservative assumptions for integration friction, or the back half of the year carries tougher comparisons or seasonal step-downs. For a company that just added two acquisition platforms, the conservative interpretation is the more straightforward one. Integration costs, channel overlap, and purchase accounting adjustments can mute reported profitability even as revenue arrives. The Q1 print tells you the deals are booking; the second-quarter call will tell you whether those bookings are converting into margin-accretive revenue or simply padding the top line.

Margin Delivery After TYR and Alien Gear: The Next Test

The earnings call flagged margin outlook, and that is where the setup gets tested. TYR Tactical is a provider of protective equipment to military and law enforcement buyers, a customer set known for demanding customized products that can compress gross margins. Alien Gear Holsters operates in the consumer and professional holster market, a faster-turn business that introduces a different fulfillment and marketing cost structure. Both deals add revenue; neither automatically adds at Cadre’s historical margin profile.

If Cadre can hold–or expand–its operating margins while integrating these acquired businesses, the stock re-rates because the market is not pricing that outcome. AlphaScala’s proprietary Alpha Score for CDRE sits at 34 out of 100, a Weak rating that reflects elevated valuation relative to insider activity and institutional flow patterns. A low Alpha Score does not call a top; it signals that current pricing already discounts a clean execution path. Any margin slip, even on strong revenue, would therefore have an outsized impact on the stock.

The next test arrives with the quarterly 10-Q filing. That document will break out organic versus acquired revenue, reveal the acquisition-date balance sheet, and show the adjusted operating profit net of purchase accounting. Until those numbers land, the record backlog and reaffirmed guide are a setup, not a thesis. For the full Cadre dashboard, including Alpha Score, valuation, and institutional flow data, see the CDRE stock page. For broader sector context, visit our stock market analysis.

The post-earnings question is not whether the $355 million backlog supports $736 million to $758 million in sales. It is whether the margin that comes with those sales justifies the price. The answer arrives in the next filing.